Xbrane BiopharmaHigh Demand Complex Generics

“Xbrane’s technology has the potential to be of central importance to protein production in the biopharmaceutical industry – a market estimated at over USD 100 billion per annum”

Xbrane_1

Xbrane_2

Xbrane_4

Spherotide-box

About Xbrane Biopharma

Xbrane is a biopharmaceutical company specialized in the development and production of high demand complex generics. The company focuses on two specific market segments; generics with slow release formulation and biosimilars.

Xbrane has a patented technology and deep know-how in protein production in E.coli and the company is one of few companies in the world that has the technological know-how to develop and produce generics to drugs with a controlled release formulation based on biodegradable microspheres.

The patented protein production technology enables a significantly more cost efficient production process of biological drugs compared to standard systems in bacteria cells of the form E.coli and the technology makes it possible for Xbrane to introduce affordable generic versions (or biosimilars) of critical biological drugs in developing countries as well as to realize significant cost savings for burdened health care systems in the developed countries.

Complex pharmaceuticals within Xbrane’s niche area, with expired patent, has a revenue of approximately 300 billion SEK. Xbranes current product portfolio includes eight product candidates addressing a global market estimated at 95 billion SEK. The original companies leading products, Spherotie and Xlucane, addresses a market where the original pharmaceuticals have a turnover of approximately SEK 40 billion globally

Xbrane Biopharma is listed on Nasdaq First North since February 2016.

Contact

8

MARTIN ÅMARK
CEO

+46 (0)76 309 37 77
martin.amark@xbrane.com

Xbrane Biopharma AB
Stureplan 15
SE-111 45 Stockholm
Sweden

www.xbrane.com
info@xbrane.com

Xbrane-Biopharma-logo-grey-298px